624 related articles for article (PubMed ID: 19040525)
1. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma.
Miyazaki J; Nishiyama H; Yano I; Nakaya A; Kohama H; Kawai K; Joraku A; Nakamura T; Harashima H; Akaza H
Anticancer Res; 2011 Jun; 31(6):2065-71. PubMed ID: 21737624
[TBL] [Abstract][Full Text] [Related]
3. The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands.
Miyazaki J; Kawai K; Kojima T; Oikawa T; Joraku A; Shimazui T; Nakaya A; Yano I; Nakamura T; Harashima H; Akaza H
BJU Int; 2011 Nov; 108(9):1520-6. PubMed ID: 21314815
[TBL] [Abstract][Full Text] [Related]
4. New packaging method of mycobacterial cell wall using octaarginine-modified liposomes: enhanced uptake by and immunostimulatory activity of dendritic cells.
Homhuan A; Kogure K; Akaza H; Futaki S; Naka T; Fujita Y; Yano I; Harashima H
J Control Release; 2007 Jul; 120(1-2):60-9. PubMed ID: 17467840
[TBL] [Abstract][Full Text] [Related]
5. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.
Lee CF; Chang SY; Hsieh DS; Yu DS
Cancer Gene Ther; 2004 Mar; 11(3):194-207. PubMed ID: 14973549
[TBL] [Abstract][Full Text] [Related]
6. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
[TBL] [Abstract][Full Text] [Related]
7. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.
Horinaga M; Harsch KM; Fukuyama R; Heston W; Larchian W
Urology; 2005 Aug; 66(2):461-6. PubMed ID: 16040105
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
Yu DS; Lee CF; Hsieh DS; Chang SY
Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
[TBL] [Abstract][Full Text] [Related]
9. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
[TBL] [Abstract][Full Text] [Related]
10. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.
Yoshino T; Miyazaki J; Kojima T; Kandori S; Shiga M; Kawahara T; Kimura T; Naka T; Kiyohara H; Watanabe M; Yamasaki S; Akaza H; Yano I; Nishiyama H
PLoS One; 2019; 14(1):e0209196. PubMed ID: 30608942
[TBL] [Abstract][Full Text] [Related]
11. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
12. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
Vaage J
Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
[TBL] [Abstract][Full Text] [Related]
13. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
[TBL] [Abstract][Full Text] [Related]
14. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
15. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
[TBL] [Abstract][Full Text] [Related]
16. Immunological protection induced by bacillus Calmette-Guérin treatment in a murine bladder tumor model.
Iwasaki A; Kawai K; Hayashi H; Ikeda N; Toida I; Ohtani M; Akaza H
Int J Urol; 2002 Apr; 9(4):219-24. PubMed ID: 12010317
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
Lee CF; Chang SY; Hsieh DS; Yu DS
J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E
Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of interleukin-12 against murine bladder cancer.
Eto M; Harada M; Tamada K; Tokuda N; Koikawa Y; Nakamura M; Nomoto K; Naito S
J Urol; 2000 May; 163(5):1549-52. PubMed ID: 10751886
[TBL] [Abstract][Full Text] [Related]
20. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
Chen F; Zhang G; Cao Y; Hessner MJ; See WA
J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
